Parameter | Estimate | RSE | LLP 95% CI | RSE/RSE Prior | |
---|---|---|---|---|---|
Lower | Upper | ||||
% | |||||
CLpac (l/h) | 378 | 8.4 | 322 | 441 | |
V1 (liters) | 188 | 11 | 0.66 | ||
V2 (liters) | 1100 | 8.2 | 0.54 | ||
V3 (liters) | 222 | 14 | 0.68 | ||
Q2 (l/h) | 123 | 10 | 0.45 | ||
Q3 (l/h) | 181 | 13 | 0.57 | ||
Blin | 7.89 | 10 | 0.84 | ||
BCrEL | 3.62 | 9.1 | 0.91 | ||
Bmax (μmol/l) | 0.0207 | 22 | 0.81 | ||
Km (μmol/l) | 0.000123 | 36 | 0.83 | ||
ε1, pac (%) | 24.4 | 4.7 | 22.3 | 26.8 | |
IIVCLpac (CV %)a | 15.3 | 39b | 10.0 | 22.3 | |
IIVBlin (CV %)a | 101 | 34b | 67.3 | 176 | |
CL6αOH/fmpac (l/h) | 2830 | 26 | 1850 | 4750 | |
V6αOH/fmpac (liters) | 1390 | 24 | 945 | 2230 | |
BCrEL, 6αOH | 43.0 | 40 | 24.4 | 99 | |
Bnsp, 6αOH (μmol/l) | 0.000754 | 12 | 0.000588 | 0.000947 | |
ε1, 6αOH (%) | 25.4 | 5.6 | 22.9 | 28.4 | |
ε2, 6αOH, i=1 (μmol/l) | 0.00447 | 30 | 0.00250 | 0.00772 | |
IIVCL6αOH/fmpac (CV %)a | 36.6 | 36b | 25.1 | 53.8 | |
CLp3OH/fmpac (l/h) | 1470 | 16 | 1090 | 2020 | |
Vp3OH/fmpac (l/h) | 1140 | 13 | 883 | 1490 | |
BCrEL, p3OH | 8.60 | 32 | 5.24 | 16.1 | |
Bnsp, p3OH (μmol/l) | 0.00124 | 10 | 0.00103 | 0.00149 | |
ε1, p3OH (%) | 37.7 | 4.8 | 34.5 | 41.6 | |
IIVfp3OH/fmpac | 0.425c | 29b | 0.245c | 0.769c | |
CrEL50 (ml/l) | 4.48 | 18 | 3.55 | 6.21 | |
HillCrEL | 2.71 | 13 | 2.20 | 3.39 | |
IIVHillCrEL (CV %)a | 40.1 | 38b | 26.8 | 58.9 | |
CLdiOH/fmmet (l/h) | 831 | 15 | 606 | 1140 | |
VdiOH/fmmet (liters) | 167 | 23 | 97.1 | 246 | |
ε1, diOH (%) | 49.8 | 8.4 | 42.6 | 59.3 | |
ε2, diOH (μmol/l) | 0.00197 | 22 | 0.00134 | 0.00315 | |
IIVCLdiOH/fmmet (CV %)a | 60.7 | 39b | 40.8 | 104 |
CLpac, clearance of unbound concentrations of paclitaxel; V1, V2, and V3, volumes of the central, first, and second peripheral compartment for unbound concentrations of paclitaxel; Q2 and Q3, intercompartmental clearances between the central and peripheral compartments for unbound concentrations of paclitaxel; Blin, linear binding to plasma components; BCrEL, binding directly proportional to CrEL concentration; Bmax, maximal binding to plasma components; Km, concentration at half of the maximal binding to plasma components; CL6αOH/fmpac and CLp3OH/fmpac, clearance of unbound concentrations of 6αOH-pac and p3OH-pac over fraction metabolized unbound paclitaxel; V6αOH/fmpac and Vp3OH/fmpac, volume of distribution of unbound concentrations of 6αOH-pac and p3OH-pac over fraction metabolized unbound paclitaxel; BCrEL, 6αOH and BCrEL, p3OH, maximal binding rate to CrEL of 6αOH-pac and p3OH-pac; Bnsp, 6αOH and Bnsp, p3OH, nonspecific CrEL component for 6αOH-pac and p3OH-pac; CrEL50, CrEL concentration at half-maximal binding rate; HillCrEL, Hill coefficient for CrEL concentration; CLdiOH/fmmet, clearance of unbound concentrations of diOH-pac over fraction metabolized unbound primary metabolite; VdiOH/fmmet, volume of distribution of unbound concentrations of diOH-pac over fraction metabolized unbound primary metabolite; ε1, proportional residual error for total concentrations; ε2, 6αOH, i=1, additive error for first sample for each individual of total concentration of 6αOH-pac; ε2, diOH, additive error for total concentration of diOH-pac; IIVCLpac, IIVBlin, IIVCL6αOH/fmpac, IIVfp3OH/fmpac, IIVHillCrEL, IIVCLdiOH/fmmet, interindividual variability in the designated parameter.
↵a Coefficient of variation, calculated as [exp(ω2) − 1]0.5.
↵b With respect to the variance term, ω2.
↵c Estimate given for the corresponding variance term, ω2, of β in eqs. 5 and 6.